Henry Schein Inc
XMUN:HS2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (23.6), the stock would be worth €69.6 (3% upside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 22.8 | €67.25 |
0%
|
| 3-Year Average | 23.6 | €69.6 |
+3%
|
| 5-Year Average | 22 | €64.66 |
-4%
|
| Industry Average | 23 | €67.85 |
+1%
|
| Country Average | 23.2 | €68.41 |
+2%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Henry Schein Inc
XMUN:HS2
|
9B EUR | 22.8 | 22.6 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
101.9B USD | 10.7 | 23.5 | |
| US |
|
Cencora Inc
NYSE:COR
|
59.9B USD | 18.3 | 36.9 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
59.4B USD | 18.1 | 36.6 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
47.2B USD | 9.6 | 28.4 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32.1B AUD | 62.4 | 35.3 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
62.9B CNY | 19.6 | 11 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
59.8B CNY | 161.9 | 21.1 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | -285 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
61B HKD | 0.6 | 7.6 | |
| DE |
M
|
McKesson Europe AG
XHAM:CLS1
|
5B EUR | 19.8 | -5.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.4 |
| Median | 23.2 |
| 70th Percentile | 35.1 |
| Max | 3 178 983.5 |
Other Multiples
Henry Schein Inc
Glance View
In the evolving landscape of healthcare distribution, Henry Schein Inc. has carved out a robust niche, establishing itself as a pivotal player in delivering essential products and services. Founded in 1932, the company initially responded to the growing need for medical supplies with a simple commitment to customer service and innovation. Today, the company profiles as the world’s largest provider of healthcare products and services to office-based dental and medical practitioners, alongside its veterinary arm. It services a global footprint, channeling its efforts into dental, medical, and animal health sectors. The company's sprawling network deploys a vast array of products—from consumables to equipment—to a multitude of healthcare professionals, accentuating its integral role in the clinical toolkit. Henry Schein's revenue engine thrives on a meticulously crafted business model that combines the breadth of a comprehensive catalog with targeted value-added services. Its diverse product offerings span dental implants, vaccines, pharmaceuticals, and surgical supplies, delivered through direct sales and sophisticated logistical frameworks. Moreover, Henry Schein supplements its product lines with a suite of services, including practice management solutions and e-commerce platforms, that streamline operations for practitioners and enhance client loyalty. Strategic partnerships and acquisitions show the company's commitment to innovation, driving efficiencies and expanding its reach. This continuous adaptation keeps Henry Schein at the forefront of healthcare trends, ensuring steady streams of income flowing from both longstanding relationships and new market opportunities.